Deals this week: Verastem, Caladrius Biosciences, Reata Pharmaceuticals

27th July 2018 (Last Updated July 27th, 2018 00:00)

US-based drug development company Verastem plans to raise $200m through a public offering of securities.

US-based drug development company Verastem plans to raise $200m through a public offering of securities.

The company plans to offer and sell the securities periodically in the form of common stock, preferred stock, debt securities, and warrants.

The proceeds are planned to be used towards working capital, research and development, and clinical development of its drug conjugates.

Ropes & Gray has been appointed as the legal adviser to the company for the offering.

Caladrius Biosciences plans to raise $150m through a public offering of securities.

The company plans to offer the securities periodically in the form of common stock, preferred stock, debt securities, and warrants.

Based in the US, Caladrius Biosciences is a biopharmaceutical company focused on the development of stem cell therapies and regenerative medicines.

Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. has been appointed as the company's legal adviser for the offering.

The company plans to use proceeds from the offering towards working capital, research and development, and general corporate purposes.

Reata Pharmaceuticals has raised $216m through an underwritten public offering of three million shares of its class A common stock, priced at $72 a share.

The underwriters will have a 30-day option to buy an additional 0.45 million shares of the company’s common stock.

"Caladrius Biosciences plans to raise $150m through a public offering of securities."

Vinson & Elkins has been appointed as the legal adviser to the company for the offering.

The transaction is expected to be closed in July 2018, subject to customary closing conditions.

Based in the US, Reata Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of experimental oral anti-oxidative and anti-inflammatory drugs.

The funds raised from the offering are intended to be used towards clinical development of its potential drug candidates, working capital, and other general corporate purposes.

Azafaros has raised funds through a seed financing round from Netherlands-based investor BioGeneration Ventures (BGV).

Also based in the Netherlands, Azafaros develops therapeutic agents for the treatment of rare metabolic disorders.

The company plans to use the funds to develop novel treatments for metabolic disorders.

Gossamer Bio has raised $230m through a series B financing round from Hillhouse Capital.

New and existing investors participated in the funding round.

Based in the US, Gossamer is a biopharmaceutical company engaged in the discovery and development of immunology-based therapeutics.

The company plans to use the funds towards business development activities and clinical development of its early and late-stage drug products.